I'm not sure exactly what you mean by 'end-run' but there are massive opportunities in biotech for reading the letter of the law and understanding what you can do that other people don't realize.

For instance my company (Glowing Plant, YC S14) is entirely predicated on such an understanding. We read the rules and realized that if we engineered a plant with a gene gun instead of agrobacterium it would not be regulated in the United States. This saves us millions of dollars in getting a product to market and means we can pursue an agile product development strategy. Game changer.

I'm aware of another 4-5 such opportunities for syn bio products where you can get to market for low or zero regulatory permission.